<DOC>
	<DOCNO>NCT00723073</DOCNO>
	<brief_summary>Invasive fungal infection important cause morbidity mortality patient neutropenia receive chemotherapy cancer . Early diagnosis infection difficult fever may sign . A delay treatment diagnosis pursue may lead increased morbidity mortality . There several echinocandins available similar vitro spectrum activity . Caspofungin echinocandin Food Drug Administration ( FDA ) approve empiric antifungal therapy febrile neutropenia . Although echinocandin antifungal agent similar spectrum activity , limit data use micafungin patient persistent fever neutropenia ( FN ) . In November 2006 Pharmacy Therapeutics Committee Brigham &amp; Women 's Hospital / Dana Farber Cancer Institute ( BWH/DFCI ) switch caspofungin micafungin formulary echinocandin . Given limited clinical data use micafungin empiric antifungal therapy patient FN , seek evaluate safety effectiveness micafungin , compare caspofungin , indication use sequential cohort analysis patient treat formulary change Brigham Women 's Hospital .</brief_summary>
	<brief_title>Caspofungin Micafungin Empiric Antifungal Therapy Persistent Fever Neutropenia</brief_title>
	<detailed_description>Objectives This retrospective cohort analysis convert caspofungin micafungin empiric antifungal therapy cancer patient persistently febrile neutropenic receive broad spectrum antibiotic Brigham &amp; Women 's Hospital / Dana Farber Cancer Institute ( BWH/DFCI ) design evaluate follow objective : - Safety micafungin patient population - Effective dose 100 mg daily micafungin compare 70mg x1 , 50 mg daily caspofungin - Economic impact convert formulary echinocandin micafungin caspofungin Study Design - Retrospective cohort analysis - limited medical record - Data collect include following : - Demographic information : include : gender , age , race - Past medical history admit diagnosis - Laboratory result : Liver function test ( LFTs ) , Including alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , Total bilirubin , well serum fungal assay : Serum Galactomannan assay , 1.3-BD Glucan assay - Concomitant medication duration therapy systemic : antibiotic antifungal - All invasive breakthrough fungal infection detail , include speciation outcomes echinocandin therapy - Dosing , duration , adverse event associate echinocandin therapy</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<criteria>All patient admit BWH/DFCI receive least 2 dos caspofungin Absolute Neutrophil Count ( ANC ) &lt; 500 , persistent febrile neutropenia 11/1/2005 10/31/2006 , first antifungal agent . All patient admit BWH/DFCI receive least 2 dos micafungin Absolute Neutrophil Count ( ANC ) &lt; 500 persistent febrile neutropenia 11/1/2006 10/31/2007 first antifungal agent Patients receive echinocandin antifungal agent ( micafungin caspofungin ) indication empiric therapy febrile neutropenia Patients receive therapy active ongoing invasive fungal infection Patients receive caspofungin micafungin admission Patients ANC &gt; 500 either micafungin caspofungin start Patients receive another antifungal agent persistent febrile neutropenia , e.g. , voriconazole , amphotericin B liposome , posaconazole , etc ... Before receive echinocandin ( caspofungin micafungin ) exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>micafungin , caspofungin , febrile neutropenia</keyword>
</DOC>